Literature DB >> 2046469

Disturbed cholecystokinin secretion in patients with eating disorders.

E Phillipp1, K M Pirke, M B Kellner, J C Krieg.   

Abstract

It has been shown that the gastrointestinal hormone cholecystokinin (CCK) induces satiety and reduces food intake in laboratory animals and humans. In the light of this evidence we studied CCK release in patients suffering from eating disorders. The secretion of CCK into the general circulation was measured in 10 anorectic, in 7 bulimic patients, and in 8 healthy controls before and after a high-caloric liquid testmeal. Baseline CCK values were similar in controls (0.6 +/- 0.2 pmol/l) and bulimics (0.6 +/- 0.1 pmol/l) and were significantly increased in the anorectic group (1.8 +/- 0.4 pmol/l) (p less than or equal to 0.005). After eating peak plasma levels increased to 6.1 +/- 0.9 pmol/l in the anorectic, to 3.8 +/- 0.5 pmol/l in the bulimic and to 2.7 +/- 0.6 pmol/l in the control group. All postprandial CCK values were significantly higher in the anorectic group. The secretion of CCK-8-S, an important peptide in the CCK family, was significantly elevated, too. This disturbed CCK secretion in patients suffering from anorexia nervosa, even if it is a secondary, diet-induced defect, may perpetuate this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046469     DOI: 10.1016/0024-3205(91)90379-p

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Gastric emptying and symptoms of bulimia nervosa: effect of a prokinetic agent.

Authors:  Michael J Devlin; Harry R Kissileff; Ellen J Zimmerli; Francine Samuels; Benny E Chen; Amanda J Brown; Allan Geliebter; B Timothy Walsh
Journal:  Physiol Behav       Date:  2012-02-14

Review 2.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Normal gastric antral myoelectrical activity in early onset anorexia nervosa.

Authors:  A M Ravelli; B A Helps; S P Devane; B D Lask; P J Milla
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

4.  Ghrelin: central and peripheral implications in anorexia nervosa.

Authors:  Mathieu Méquinion; Fanny Langlet; Sara Zgheib; Suzanne Dickson; Bénédicte Dehouck; Christophe Chauveau; Odile Viltart
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-26       Impact factor: 5.555

Review 5.  Gastrointestinal peptides in eating-related disorders.

Authors:  Kimberly R Smith; Timothy H Moran
Journal:  Physiol Behav       Date:  2021-05-11

6.  Achalasia as a complication of bulimia nervosa: A case report.

Authors:  Meryem O Kutuk; Gulen Guler; Ali E Tufan; Fevziye Toros; Umut Kaytanli
Journal:  S Afr J Psychiatr       Date:  2017-02-07       Impact factor: 1.550

Review 7.  MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update.

Authors:  René Klinkby Støving
Journal:  Eur J Endocrinol       Date:  2019-01-01       Impact factor: 6.664

8.  Cholecystokinin revisited: CCK and the hunger trap in anorexia nervosa.

Authors:  Ulrich Cuntz; Paul Enck; Erich Frühauf; Peter Lehnert; Rudolf L Riepl; Manfred M Fichter; Bärbel Otto
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

Review 9.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.